成都先导与Evotec SE达成新药研发合作协议！

中国成都 2020年6月8日 成都先导药物开发股份有限公司（688222.SH）（以下简称“成都先导”）宣布已与Evotec SE达成新药研发合作，以期针对Evotec SE关注的抗感染药物领域的靶点发现全新结构的小分子化合物。成都先导将利用其以DNA编码化合物库（DNA Encoded Library，以下简称DEL）的设计、合成和筛选为核心的先进技术平台，为Evotec SE筛选针对特定靶点的先导化合物，并将这些先导化合物排他性地转让给Evotec SE。基于此协议，成都先导将收到首付款及转让许可费，具体金额未披露。

“我们很高兴与新药发现领域的领先公司Evotec SE进行合作。Evotec SE是一家新药研发和开发公司，在合作研发方面取得了巨大的成功。我们期待与Evotec SE研究团队紧密合作，为他们的项目提供新颖的小分子。”成都先导董事长兼首席执行官李进博士（JIN LI）表示。

“成都先导的DEL筛选平台具有巨大的潜力，能够帮助我们发现与特定靶标结合的小分子化合物。”Evotec SE传染病学执行副总裁Kara Carter表示。

关于Evotec SEEvotec是一家新药研发联盟和开发合作公司，致力于快速提供创新产品与方法，并与领先的制药公司、生物技术公司、学者、患者权益团体以及风险投资机构建立广泛合作。公司在全球范围内拥有3,000多名员工，提供优质自主的药物发现服务及整合式解决方案。
公司提供从“靶点到临床”的所有服务，以满足行业对药物发现和开发（EVT Execute业务）的创新和效率的需求。通过组建一流的科学专家，整合最新技术以及在关键治疗领域所获得的丰富经验和专业知识，公司业已建立了独有的行业地位。这些关键领域涵盖广泛，包括神经元疾病，糖尿病和糖尿病并发症，疼痛和炎症，肿瘤学，传染病，呼吸系统疾病，纤维化，罕见疾病和妇女健康。
在此基础上，Evotec在临床、临床前和早期发现阶段（EVT Innovate 业务）广泛建立了约100个共同拥有的药物研发管线。Evotec与拜耳、勃林格殷格翰、百时美施贵宝、CHDI、诺华制药、诺和诺德、辉瑞、赛诺菲、武田，UCB等公司建立了长期合作关系。想要获得更多相关信息，请访问www.evotec.com，并关注我们的Twitter账号：@Evotec。

关于成都先导成都先导药物开发股份有限公司是一家从事新药研发的快速发展的生物技术公司，总部位于中国成都，在美国设有子公司。成都先导为小分子新药发现建立了一个国际领先的，以DNA编码化合物库的设计、合成和筛选为核心的技术平台。目前，公司基于数百种不同的骨架结构，已经完成千亿级结构全新、具有多样性和类药性DNA编码化合物的合成，并且已有多个案例证实了其针对已知靶点和新兴靶点筛选苗头化合物的能力。同时，成都先导建立了自己的新药研发管线，部分品种已进入临床实验阶段。成都先导业务遍布北美、欧洲及亚洲等，现已与多家国际著名制药公司、生物技术公司、化学公司、基金会以及科研机构建立合作，致力于新药的发现与应用。

获取更多信息，请致电+ 86-28-85197385或访问www.hitgen.com 。媒体查询：[e-mail] 投资者咨询：[e-mail] 业务发展：[e-mail] 

HitGen and Evotec SE Enter Into

Drug Discovery Research Collaboration

CHENGDU, China, June 8, 2020 -- HitGen (688222.SH) announced that it has entered into a drug discovery research collaboration with Evotec SE to identify small molecule leads against targets of interest to Evotec SE in the field of anti-infectives. HitGen will apply its platform technology, based on the design, synthesis and screening of DNA-encoded libraries (DEL) to discover compounds that bind to certain targets. The identified compounds will be exclusively licensed to Evotec SE. Under the terms of the agreement, HitGen will receive an undisclosed upfront payment and license fee from Evotec SE.
“We are delighted to enter this collaboration with Evotec SE, a leading drug discovery alliance and development partnership company with tremendous success in collaborative R&D. We look forward to working closely with Evotec SE research teams to deliver novel small molecules to their programs, ” said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen.
“HitGen’s DEL screening platform offers tremendous potential to identify a small molecule binder to Evotec’s target of interest”, said Kara Carter, Executive Vice President Infectious Disease from Evotec SE.
About Evotec SEEvotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,000 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women’s health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.
About HitGen Inc.HitGen is a rapidly growing biotech company with headquarters based in Chengdu, China, with a subsidiary in the USA. HitGen has established an industry-leading platform for early-stage drug discovery research centered on DNA encoded chemical libraries (DELs). HitGen’s DELs include encoded syntheses for hundreds of billions of novel, diverse, drug-like small molecule and macrocycle compounds. These compounds are members of DELs synthesized from many hundreds of distinct chemical scaffolds, designed and assembled with tractable chemistry based on proven results for identifying drug-like leads against biological targets from known and novel classes. HitGen is working with multiple pharmaceutical and biotech companies, foundations and research institutes in North America, Europe and Asia to discover and develop novel therapeutics of the future.
For more information, please call [phone] or visit www.hitgen.com.For media inquiries: [e-mail] investor inquiries: [e-mail] business development: [e-mail]

RECOMMEND
本周推荐阅读

关于药融圈

药融圈围绕我国生物医药产业链，针对生物医药大数据、技术和资本投资、药融园(产业园)等开展系列系统性工作，促进我国生物医药产业健康发展，完善产业链，共同面对全球合作和竞争。

联系我们

上海总部地址：上海市浦东新区秋月路26号 矽岸国际一号楼四楼B座

医药一级项目投融资合作：

[e-mail]

咨询/会议/媒体PR合作 ：

[e-mail]

戳原文，即可进入药融圈官网